Manyetik Rezonans Görüntüleme Kontrast Maddeleri ve Yan Etkileri Türkçe

Abstract

Manyetik Rezonans görüntülemede kontrast maddeler 1980'li yıllardan beri kullanılmaktadır. Kontrast maddelerin aktif biçimde kullanılmaya başlanması ile manyetik rezonans görüntülemenin birçok konuda çok başarılı bir radyolojik görüntüleme yöntemi haline geldiği görülmektedir. Manyetik rezonans incelemelerinde kontrast madde kullanımının günümüzde hızla artmasıyla birlikte bunun getirdiği sorunlar da artmaktadır. Özellikle son yıllarda gadolinyumlu kontrast ajanlar ile ilişkili olarak ortaya çıkan nefrojenik sistemik fibrozis önemli sorunlardan birisidir. Günümüzde manyetik rezonans incelemelerinde sıklıkla kullanılan kontrast maddeler ile ilgili ortaya çıkabilecek sorunlar ve bunları önleme yöntemlerinin bilinmesi gerekli olup bu konu ile ilgili bilgiler sürekli olarak güncellenmelidir

Keywords

• Manyetik rezonans görüntüleme,kontrast madde,nefrojenik sistemik fibrozis

Magnetic resonance imaging contrast agents and side effects

Abstract

Magnetic resonance imaging contrast agents have being used since the 1980s. Since the use of magnetic resonance imaging contrast agents actively, magnetic resonance imaging has become a very successful radiological imaging modality in many aspects. Today the usage of magnetic resonance imaging contrast agents is increasing rapidly with the increase of accompanying problems. Especially in recent years, nephrogenic systemic fibrosis is an important problem arising, associated with gadolinium contrast agents. Recently, the knowledge of problems that can occur with the usage of contrast agents in magnetic resonance imaging examinations and the knowledge of methods that can be used for overcoming these problems are necessary, and the information with this issue should be constantly updated

Keywords

• Magnetic resonance imaging,contrast agent,nephrogenic systemic fibrosis

References

1. ) De Haen C. Conception of the first magnetic resonance imaging contrast agents: a brief history. Top Magn Reson Imaging 2001; 12: 221-30.
2. ) Westbrook C, Kaut C. MRI in Practice, 2th ed, Blackwell Science. 1998; 215-8.
3. ) Kirchin MA. Runge VM. Contrast Agents for Magnetic Resonance Imaging: Safety Update. Topics in Magnetic Resonance Imaging 2003; 14: 426-35.
4. ) Reimer P, Schneider G, Schima W. Hepatobiliary Contrast Agents For Contrast- enhanced MRI of the Liver:properties, clinical development and applications. Eur Radiol ; 14: 559-78. ) Sheppard D,Allan L, Martin P, Mc Leay T, Milne W, Houston JG. Contrast-enhanced magnetic resonance cholangiography using mangafodipir compared with Standard T2W MRC sequences: a pictorial essay. J Magn Reson Imaging 2004; 20: 256-63.
5. ) Semelka RC. Abdominal-Pelvic Imaging. baskı, Willey-Liss, 2002; 35-41.
6. ) Runge VM. Safety of approved MR contrast media for intravenous injection. J Magn Reson Imaging 2000; 12: 205–13.
7. ) Runge VM. Safety of Magnetic Resonance Contrast Media. Topics in Magnetic Resonance Imaging 2001; 12: 309-14.
8. ) Mitchell DG. MRI principles. 1st ed. Philadelphia:W.B. Saunders Company 1999; 36.

9. ) Rinck PA. Some future perspectives of contrast agent development. Clinical MRI ; 5: 129-39. ) Mahfouz AE, Hamm B. Contrast Agents. Magn Reson Imaging Clin N Am 1997; 5: 223
10. ) Earls JP, Bluemke DA. New MR Imaging Contrast Agents. Magn Reson Imaging Clin N Am 1999; 7: 255-73.
11. ) Rummeny EJ, Peters PE. MR imaging of the liver, spleen and pancreas: Imaging techniques and MR contrast agents. Clinical MRI 1995; 5: 115-20.
12. ) Weissleder R, Stark DD, Engelstad BL, et a l . S u p e r p a r a m a g n e t i c i r o n oxide:pharmacokinetics and toxicity. Am J Roentgenol 1989; 152: 167-173.
13. ) Wang YX, Hussain SM, Krestin GP. Superparamagnetic iron oxide contrast agents: pyhsicochemical characteristics and applications in MR imaging. Eur Radiol 2001; : 2319-31.
14. ) Stark DD, Weissleder R, Elizondo G, et al. Superparamagnetic iron oxide: clinical application as a contrast agent for MR imaging of the liver. Radiology 1988; 168: 301.
15. ) Frank H, Weissleder R, Brady TJ. Enhancement of MR angiography with iron oxide: Preliminary studies in whole-body phantom in animals. AJR 1994; 162: 209-13.
16. ) Normann PT, Hustvedt SO, Storflor H, et al. Preclinical safety and pharmacokinetic profile of gadodiamide injection. Clinical MRI ;5: 95-101. ) Rohrer M, Bauer H, Mintorovitch J, Requardt M, Weinmann HJ. Comparison of Magnetic Properties of MRI Contrast Media Solutions at different Magnetic Field Strengths. Invest Radiol 2005; 40: 715-24.
17. ) Schmitt-Willich H. Stability of linear and macrocyclic gadolinium based contrast agents. Br J Radiol 2007; 80: 581-2.
18. ) Kuo PH, Kanal E, Abu-Alfa AK, Cowper SE. Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis. Radiology ; 242: 647-9. ) Grobner T. Gadolinium; a spesific trigger for development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis. Nephrol Dial Transplant 2006; 21: 8.
19. ) Rofsky NM, Sherry DA, Lenkinski LE. Nephrogenic systemic fibrosis: a chemical perspective. Radiology 2008; 247: 608-12.
20. ) Lin SP, Brown JJ. MR contrast agents: physical and pharmacologic basics. J Magn Reson Imaging 2007; 25: 884-99.
21. ) Wertman R, Altum E, Martin DR, et al. Risk of nephrogenic systemic fibrosis: evaluation of gadolinium chelate contrast agents by four American universities. Radiology 2008; 248: 799-806.
22. ) ESMRMB Recommendation on adverse reactions to gadolinium based contrast agents (Gd-CA), June 2008; Available at
23. (http://www.esmrmb.org/html/img/pool/ESM R M B _ _ r e c o m m e n d a t i o n _ o n _ N S F. p d f ) Accessed on: 06.06.2008
24. ) Karabulut N, Elmas N. Contrast agents used in MR imaging of the liver. Diagn Interv Radiol 2006; 12: 22-30.
25. ) Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit PE. Scleromyxoedema- like cutaneous diseases in renal-dialysis patients. Lancet 2000; 356: 1000–1.
26. ) Cowper SE, Su LD, Bhawan J, Robin HS, LeBoit PE. Nephrogenic fibrosing dermopathy. Am J Dermatopathol 2001; 23: 383–93.
27. ) Mendoza FA, Artlett CM, Sandorfi N, Lanitis K, Piera-Velazquez S, Jimenez SA. Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature. Semin Arthritis Rheum 2006; 35: 49.
28. ) MRI Contrast Agents and Nephrogenic Systemic Fibrosis (NSF), Available at: http://www.mrisafety.com/safety_article.asp?s ubject=204. ) Halvorsen RA. Which Study When? Iodinated Contrast-enhanced CT Versus Gadolinium-enhanced MR Imaging. Radiology ; 249: 9-15. ) Weinreb JC. Which Study When? Is Gadolinium-enhanced MR Imaging Safer than Iodine-enhanced CT? Radiology 2008; 249: 3